Active, not recruitingEarly Phase 1NCT07517068

The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude

Studying Ablepharon macrostomia syndrome

Last synced from ClinicalTrials.gov May 10, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of California, Riverside
Intervention: ACETAZOLAMIDE oral capsule(drug)
Enrollment: 19 enrolled
Eligibility: 18-65 years · All sexes
Timeline: 2025 – 2026

Study locations (1)

University of California, Riverside, Riverside, California, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07517068 on ClinicalTrials.gov

← Back to all trials